Component

Rosuvastatin

More hydrophilic statin used as the within-study comparator.

1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

Where it participates (unsigned role)

  1. The same SLCO1B1 c.521CC genotype raised rosuvastatin exposure by 65 percent, a smaller effect than on atorvastatin, which the authors describe as unexpected for the more hydrophilic statin.

    Experimental context and source evidence
    duration
    Single dose with 48-hour sampling
    evidence_access
    Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    experimental_model
    The same 32 healthy volunteers
    exposure
    Single 10 mg oral rosuvastatin dose, one week apart from the atorvastatin dose
    limitations
    A within-study comparison of two statins at different doses, so the ratio of effects is not a dose-matched comparison.
    organism
    The same 32 healthy volunteers
    plain_language
    The same SLCO1B1 c.521CC genotype raised rosuvastatin exposure by 65 percent, a smaller effect than on atorvastatin, which the authors describe as unexpected for the more hydrophilic statin.
    primary_references
    Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. (2007). https://pubmed.ncbi.nlm.nih.gov/17473846/ DOI: 10.1038/sj.clpt.6100220
    route
    Oral
    tissue
    Plasma rosuvastatin area under the concentration-time curve and peak concentration

    OATP1B1 activity and statin exposure: the step between transporter inhibition and drug concentration (2026-09-22) · lines 46–55

    Original AI-assisted curation of four primary studies resolved by PubMed title search and cross-checked against live PubMed metadata. Three of the four share one research group and are recorded as one line of evidence. Study-specific citations, doses and limitations retained. Not publisher full text. · supports · · source_derived_draft · unverified_draft

    ## slco1b1-c521cc-raises-rosuvastatin-exposure-less The same SLCO1B1 c.521CC genotype raised rosuvastatin exposure by 65 percent, a smaller effect than on atorvastatin, which the authors describe as unexpected for the more hydrophilic statin. Model/species: The same 32 healthy volunteers Tissue/system: Plasma rosuvastatin area under the concentration-time curve and peak concentration Exposure: Single 10 mg oral rosuvastatin dose, one week apart from the atorvastatin dose Route: Oral Duration: Single dose with 48-hour sampling Limits: A within-study comparison of two statins at different doses, so the ratio of effects is not a dose-matched comparison. Primary reference: Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. (2007). https://pubmed.ncbi.nlm.nih.gov/17473846/ DOI: 10.1038/sj.clpt.6100220 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards